Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an open label safety and feasibility trial using Acthar® in addition to the
investigators center-specific standard therapy, which could include increase in maintenance
immunosuppression, high dose IVIG (2 g/Kg), and/or Rituximab, in patients with CAMR.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore